The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The company does not expect this development to have any material impact on the current business operations
The supply of these goods is set to commence within the first quarter of FY26
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
Subscribe To Our Newsletter & Stay Updated
